Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Infinimmune raises $75 million in Series A financing to advance its pipeline of human-derived antibodies for atopic dermatitis and inflammatory disease.
PRIVATEAug 11, 2026•about 4 hours ago
Amount Raised
$75 Million
Round Type
Series A
AlamedaBiotechnologyHealth CareTherapeutics
Description
Infinimmune has successfully raised $75 million through a Series A financing round. The funding will be utilized to advance their pipeline of human-derived antibodies. This investment is critical for their ongoing research into treatments for atopic dermatitis and inflammatory diseases. The company aims to enhance its product development and expand its market presence.
Company Information
Company
Infinimmune
Location
Alameda, California, United States
About
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications.
Related People
Suggested for you
1 contact
Verified contactsNo contacts on file at Infinimmune yet.
Predictive Intelligence
Strategic
ML-powered predictions for Infinimmune's next move
AlamedaBiotechnologyHealth CareTherapeutics